NEW YORK, Sept 25 | Wed Sep 25, 2013 12:39pm EDT




(Reuters) - Medical technology provider Cognoptix, which is developing a test for early detection of Alzheimer's Disease, is discussing putting itself up for sale, a person familiar with the situation told Reuters.



The Acton, Massachusetts-based company is working on a test that would detect Alzheimer's Disease in a patient through a scan of the eyes.



Since the company is privately held, it is unclear how much it would be worth in a sale.



Cognoptix has tapped Milwaukee-based Robert W. Baird & Co to help with its discussions and handle a sale process if it goes that route, said the source, who asked to remain anonymous because the situation is confidential.



Calls and e-mails to Baird and Cognoptix were not returned.



On Monday, Cognoptix released data from a multi-site trial that showed its SAPPHIRE II eye test was able to differentiate Alzheimer's patients from healthy volunteers in a majority of cases.



(Reporting by Jessica Toonkel; Editing by John Wallace)


0 comments:

Post a Comment

 
Top